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ABSTRACT: Protein engineering and formulation optimization strategies can
be taken to minimize protein aggregation in the biopharmaceutical industry.
Short-term stability measures such as the midpoint transition temperature
(Tm) for global unfolding provide convenient surrogates for longer-term (e.g.,
2-year) degradation kinetics, with which to optimize formulations on practical
time-scales. While successful in some cases, their limitations have not been
fully evaluated or understood. Tm values are known to correlate with chemical
degradation kinetics for wild-type granulocyte colony stimulating factor
(GCSF) at pH 4−5.5. However, we found previously that the Tm of an
antibody Fab fragment only correlated with its rate of monomer loss at temperatures close to the Tm. Here we evaluated Tm, the
fraction of unfolded protein ( f T) at temperature T, and two additional short-term stability measures, for their ability to predict
the kinetics of monomer and bioactivity loss of wild-type GCSF and four variants, at 37 °C, and in a wide range of formulations.
The GCSF variants introduced one to three mutations, giving a range of conformational stabilities spanning 7.8 kcal mol−1. We
determined the extent to which the formulation rank order diﬀers across the variants when evaluated by each of the four short-
term stability measures. All correlations decreased as the diﬀerence in average Tm between each pair of GCSF variants increased.
The rank order of formulations determined by Tm was the best preserved, with R
2-values >0.7. Tm-values also provided a good
predictor (R2 = 0.73) of the aggregation rates, extending previous ﬁndings to include GCSF variant-formulation combinations.
Further analysis revealed that GCSF aggregation rates at 37 °C were dependent on the fraction unfolded at 37 °C ( f T37), but
transitioned smoothly to a constant baseline rate of aggregation at f T37 < 10
−3. A similar function was observed previously for
A33 Fab formulated by pH, ionic strength, and temperature, without excipients. For GCSF, all combinations of variants and
formulations ﬁt onto a single curve, suggesting that even single mutations destabilized by up to 4.8 kcal mol−1, are insuﬃcient to
change signiﬁcantly the baseline rate of aggregation under native conditions. The baseline rate of aggregation for GCSF under
native conditions was 66-fold higher than that for A33 Fab, highlighting that they are a speciﬁc feature of each native protein
structure, likely to be dependent on local surface properties and dynamics.
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■ INTRODUCTION
Minimizing protein aggregation remains a major challenge to
the biopharmaceutical industry. It can occur during protein
expression,1 downstream processing (e.g., chromatography2
and ultraﬁltration/diaﬁltration3), and during storage,4 with
aggregates treated as potentially immunogenic impurities.5
Formulation and protein engineering each oﬀer potential routes
to enhance the shelf life of biopharmaceutical products.6
However, it remains a major challenge to predict molecular
variants and formulation excipients that improve stability, and
minimize aggregation. The design process for formulation is
typically semiempirical, making use of the generally observed
eﬀects of commonly used excipients, and has more recently
made use of high-throughput screening in combination with
design of experiments.7 To speed development, formulation
screens often depend on simple short-term stability measures to
create an initial rank-ordering, prior to more resource-intensive
kinetic studies at elevated temperatures, and then eventually for
longer periods at lower storage temperatures. Short-term
indicators of stability commonly include the onset temperature
(Tonset), or midpoint transition temperature (Tm) for global
conformational unfolding, as well as the onset temperature at
which aggregates are ﬁrst detected (Tagg).
The extent to which these short-term stability measures
correlate with aggregation kinetics is not generally well
characterized. Tm was found previously to correlate well with
the chemical degradation kinetics for granulocyte colony
stimulating factor (GCSF), across a modest range of
formulation.8 By contrast, the Tm-values for A33 Fab
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formulated by pH and ionic strength correlated well with
aggregation rates at elevated but not lower storage temper-
ature.9 Overall, the aggregation rates of A33 Fab, spanning eight
orders of magnitude, were found to depend on the fraction
protein unfolded until this had decreased to below approx-
imately 10−4 (0.01%). At that point, the aggregation rate was
broadly constant, with formulations leading to variations in the
aggregation rate by just over one order of magnitude. It is not
currently known whether other proteins, such as GCSF, would
show similar behavior or how this would be inﬂuenced by the
introduction of mutations that modify conformational stability.
Understanding these features would potentially enable a
convenient route for the formulation of new molecular variants,
based on the best formulations identiﬁed already for the
original variant. However, little is known about the relation-
ships between protein mutations and formulation excipients in
terms of the extent to which the rank order of formulations
changes between closely related protein variants.
GCSF is a 19.6 kDa cytokine composed of a four-helix
bundle10 (Figure 1), and its aggregation and formulation have
been studied extensively.11−14 GCSF aggregation is thought to
occur through a structurally perturbed monomer (M*), which
can either revert to monomer (M), combine to form an
aggregate dimer (M2), or combine with other aggregates into
larger species (Mx+1).
11,13,14 The aggregate dimer has not been
observed directly14 but is distinct from the reversible native
dimer observed under some conditions.13 While other proteins
may undergo more complex aggregation mechanisms, partially
unfolded intermediates are commonly observed on aggregation
pathways.15 Nonglycosylated GCSF is marketed as Filgrastim
and is formulated in 10 mM sodium acetate, 5% sorbitol,
0.004% polysorbate-80 pH 4.0.16 GCSF is most stable in low-
pH liquid formulations, which unusually does not induce a
ﬂexible “A-state” conformation, even at pH 2.0,12 whereas
physiological pH leads to more rapid aggregation.11,13 GCSF
has been studied extensively using high-throughput methods
combined with design of experiments (DoE), to generate new
liquid,17 and lyophilized7 formulations, and also to create a
range of conditions in which to assess the potential of stability
measures such as Tm and Tonset, to predict aggregation kinetics.
8
GCSF has been engineered using several experimental and
computational approaches19 to improve or modify receptor
binding20,21 or molecular stability.22−24 For example, the
computational protein design automation (PDA) approach
was used to redesigned the GCSF core and obtained mutants
with thermal midpoint transitions that had increased by up to
13 °C,22 and with no detrimental eﬀects on receptor binding.
GCSF stability has also been increased using glycine-to-alanine
(G → A) mutations,23 as these are known to increase the
enthalpy of helix formation by 0.4 to 2 kcal mol−1, and decrease
the conformational entropy of the completely unfolded state by
0.4 kcal mol−1.25,26 G26A and G28A variants stabilized WT-
GCSF with a change in the free energy of unfolding, ΔΔGunf, of
−3.06 and −2.66 kcal mol−1, respectively, while the G149A/
G150A and G28A/G149A/G150A variants were stabilized by
−4.20 and −6.16 kcal mol−1, respectively.23 Conversely, a series
of alanine-to-glycine (A → G) variants of GCSF reduced the
Tm from 57 °C in wild-type (WT-GCSF) to 52 °C (A30G), 47
°C (A29G/A30G), and 51 °C (A29G/A30G/A37G) and gave
ΔΔGunf values of +3.6 kcal mol−1 (A30G), +4.8 kcal mol−1
(A29G/A30G), and +4.6 kcal mol−1 (A29G/A30G/A37G).24
Overall, the relatively simple tertiary structure of GCSF, the
availability of several variants with altered conformational
stability, and many well characterized formulations, make it an
excellent system for exploring the relative impacts of protein
mutations and formulation excipients on overall conformational
and kinetic stability.
Previous work explored the correlation of short-term and
long-term stability measures for GCSF, in a modest range of
formulations that all retained a relatively stable protein (0−100
mM buﬀer; pH: 4.0−5.5; 0−0.05% (v/v) Tween-80; 0−5% (v/
v) HP-β-CD).8 Tm (transition midpoint) values were obtained
from the statistical normalization and combination of circular
dichroism, intrinsic ﬂuorescence, ANS binding, and light
scattering measurements, while degradation kinetics at 4−40
°C were also measured by an array of techniques. Under these
conditions, Tm data gave very good predictions of the chemical
denaturation kinetics at 4−40 °C, with an R2 of 0.87−0.96. Ton,
deﬁned as the temperature at which 20% of the normalized
transition was achieved, performed less well with an R2 of
0.44−0.71 (at 4−40 °C). While very promising, a number of
future improvements were highlighted such as expanding the
range of formulations. Several questions also remained
unanswered. For example, can other short-term measures
Figure 1. Location of substitutions within the structure of GCSF. Sites
of alanine-to-glycine substitutions are highlighted (dark pink) A29G,
(yellow) A30G, and (orange) A37G. The glycine-to-alanine
substitution G26A is highlighted purple. Images generated using
PyMol18 with GCSF structure PDBID: 2D9Q.
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predict the kinetics of monomer loss from aggregation? Would
these also apply to the kinetics for loss of bioactivity? Given the
potential of protein engineering to modify aggregation kinetics,
how well do formulation rankings for one variant predict those
of other related variants? Do aggregation mechanisms depend
on formulation conditions (e.g., pH), and how do these
changes impact on the predictive power of short-term stability
measures?
Here we have used 32 formulation designs, and a series of
single, double, and triple mutant variants of the nonglycosylated
form of GCSF, to more broadly investigate the correlations
between several short-term stability measures and degradation
kinetics. The variants included WT-GCSF, as well as one
stabilizing (G → A), and three destabilizing (A → G) GCSF
variants (Figure 1). We examined three thermal transition
measures, Ton, Tm, and Tagg, and also the fraction unfolded (fT),
determined from simultaneous measurements of static light
scattering and intrinsic protein ﬂuorescence. We compared
rankings from these stability measures across the wild-type and
four GCSF variants to determine how well their respective
rank-ordering of 32 formulations was retained. We then also
investigated the ability of the short-term measures, Tagg, Tm,
Ton, and fT, to predict the kinetics of monomer loss from GCSF
aggregation and also for loss of bioactivity. This work showed
that the impacts of mutations and excipients were not simply
additive and revealed the extent to which rank order of
formulations remain consistent across a set of protein variants
that diﬀered by only 1−3 mutations. Finally, while the work
also determined which of the four short-term stability measures
provided the best prediction of kinetic stability, we also found
that aggregation rates measured at 37 °C were directly
dependent on the fraction unfolded at 37 °C ( f T37) under
the least stabilizing conditions, but they transitioned smoothly
to a baseline rate of aggregation under conditions that retained
the Native-state population at >99.9% ( f T37 < 10
−3).
■ EXPERIMENTAL SECTION
Chemicals were supplied by the following manufacturers: acetic
acid, HEPES, arginine monohydrochloride, glutamic acid,
sucrose, and PEG 2000 (Sigma-Aldrich Co., Gillingham,
UK): Tween-80, NaCl, and trehalose (Fisher Scientiﬁc Inc.,
Loughborough, UK), Tween-20 (Santa Cruz Biotechnology
Inc., Santa Cruz, California, USA); and PEG 6000 (VWR
International Ltd., Leicester, UK).
Generation of GCSF Variants. Wild-type GCSF (acces-
sion code M17706) and the A30G, A29G/A30G and A29G/
A30G/A37G variants were expressed in E. coli BL21 DE3 from
the pET21A plasmid (Novagen, WI, USA) as described
previously.24 Wild-type GCSF in the pET21A plasmid was
mutated to create the G26A variant using the QuickChange
Lightning Site-Directed Mutagenesis Kit (Agilent Technolo-
gies, CA, USA), with the following mutagenic primers as




Mutated plasmids were transformed into XL10-Gold Ultra-
competent Cells (Agilent Technologies, CA, USA) and plated
onto LB agar with 0.1 mg/mL ampicillin. Colonies were picked
and cultured in 5 mL of LB plus 0.1 mg/mL ampicillin at 37
°C, plasmids puriﬁed with the QIAprep Spin Miniprep Kit
(Qiagen, MD, USA), then sequenced by Euroﬁns Scientiﬁc
(Acton, UK) using standard T7 promoter and T7 terminator
primers. The conﬁrmed mutated plasmid was transformed into
E. coli BL21 (DE3) competent cells (New England
Laboratories, MA, USA) for expression.
Puriﬁcation of GCSF Variants. GCSF was expressed and
puriﬁed in a modiﬁed protocol to that described previously.24
To 2 L of LB media containing 0.1 mg/mL ampicillin was
added 25 mL of overnight culture of E. coli BL21 (DE3) (from
175 mL LB containing 0.1 mg/mL ampicillin), and then
incubated at 37 °C with shaking at 150 rpm. Cells were induced
at an OD600 nm of 0.6 with a ﬁnal concentration of 1 mM IPTG
(isopropyl-thio-galacto-pyranoside), then incubated as before
for a further 3.5 h before harvesting by centrifugation. Cells
were resuspended in 500 mL of phosphate buﬀered saline
(PBS), centrifuged again, and the pellet stored at −20 °C. The
thawed pellet was resuspended in PBS at 10 mL per g of wet
cell pellet, and sonicated (10 cycles of 15 s on and 10 s oﬀ).
Lysozyme (Sigma-Aldrich Co) was then added to 1 mg/mL
and the lysate allowed to roll at room temperature for 20 min.
Sodium deoxycholate (Sigma-Aldrich Co) was added to 1 mg/
mL and rolled for 20 min, and then benzonase (Novagen, WI,
USA) added to 25 U/mL and rolled for a further 20 min. The
suspension was centrifuged 18 500g for 30 min at 10 °C. GCSF
inclusion bodies were recovered from the lysate pellet by three
successive 400 mL resuspension and centrifugation steps
(17 700g at 10 °C for 1 h, 30 min then 20 min) using (1)
50 mM Tris-HCl pH 8.0, 5 mM EDTA, 2% Triton X-100; (2)
50 mM Tris-HCl pH 8.0, 5 mM EDTA pH 8.0, 1% (w/v)
sodium deoxycholate; (3) 50 mM Tris-HCl pH 8.0, 5 mM
EDTA, 1 M sodium chloride. The ﬁnal inclusion body pellet
was resuspended in 20 mL of 2.0 M urea, the pH increased to
11.9 using dilute NaOH, then gently rolled at room
temperature for 30 min. Refolding was induced by pipetting
the urea solution in 1 mL steps, into 400 mL 1.0 M arginine
HCl (pH 8.25), and gently rolled at room temperature
overnight, then the pH adjusted to 4.25 with 50% (v/v) acetic
acid. The refolded protein solution was clariﬁed at 18 500g for
20 min at 10 °C. GCSF was concentrated using 3 kDa cutoﬀ
membrane centrifugal concentrators (Millipore, Watford, UK)
at 3000g and 10 °C, to a volume of 10 mL, clariﬁed at 18 500g
for 15 min at 10 °C, then loaded onto a XK26/60 column (GE
Healthcare, Amersham, UK) containing 350 mL of Superdex-
200 media, using an Akta Explorer (GE Healthcare). GCSF was
eluted after approximately 75 min (225 mL), using a mobile
phase of 50 mM sodium acetate pH 4.25, at 3 mL/min, and
collected as 1.8 mL fractions. GCSF was further puriﬁed by ion
exchange (IEX) chromatography using a Mono-S 5/50 column
(GE Healthcare) on an Akta Explorer and the mobile phase at
1 mL/min. After loading and initial washing at 100% buﬀer A
(10 mM sodium acetate, 10 mM NaCl pH 4.25) for 5 min,
GCSF was eluted using a gradient of 0−60% buﬀer B (10 mM
sodium acetate, 1.0 M NaCl pH 4.25) over a period of 25 min,
and collected as 0.5 mL fractions. GCSF variant sequences were
conﬁrmed by peptide mapping of 20 μL of 0.6 mg/mL GCSF
using an Orbitrap LC-MS mass spectrometer (Thermo Fisher
Scientiﬁc Inc., Loughborough, UK). Protein concentrations
were determined using an extinction coeﬃcient of 15970 M−1
cm−1 based on the protein sequence (Pace et al. 1996), and a
Nanodrop-2000 (Thermo Fisher Scientiﬁc).
Design and Preparation of Formulations. For the pH
studies of WT-GCSF, buﬀers from pH 3.5−10 were 50 mM
sodium formate pH 3.5, 50 mM sodium acetate pH 4.0, 50 mM
sodium acetate pH 5.0, 50 mM sodium phosphate-citrate pH
6.0, 50 mM sodium phosphate pH 7.0, 50 mM HEPES pH 8.0,
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and 50 mM CAPS pH 10.0. NaCl was added to all except the
sodium phosphate buﬀer, to match the 110 mM ionic strength
of that buﬀer. For the formulation studies, 28 mM of NaCl was
added to 50 mM sodium acetate pH 4.0, to bring the ﬁnal ionic
strength to the same 36 mM as that of 50 mM HEPES pH 8.0.
Design Expert 8.0 software (Stat-Ease Inc., MN, USA) was used
to generate a two-level, fractional factorial, resolution IV study,
with 32 runs as shown in Table 1, which assigns the conditions
for each run number. Factors used were pH (4.0 or 8.0), ionic
strength (36−86 mM), and excipient (0−0.1% (v/v) Tween-
20, 0−0.1% (v/v) Tween-80, 0−3.0 mg/mL PEG2000, 0−3.0
mg/mL PEG6000, 0−3.5% (w/v) sucrose, 0−3.5% (w/v)
trehalose, 0−50 mM arginine, and 0−50 mM glutamic acid).
GCSF variants were dialyzed overnight at 4 °C against each
buﬀer in Slide-a-Lyzer cassettes (ThermoFisher Scientiﬁc,
Loughborough, UK) with a 10 kDa cutoﬀ, centrifuged, then
protein concentrations redetermined and adjusted to 0.6 mg/
mL (as stocks to be used in formulations) or directly to 0.2
mg/mL (for samples with buﬀer only), with the appropriate
buﬀer. Excipient stock solutions were prepared to 1.5× for each
ﬁnal excipient concentration, in 1× of the appropriate buﬀer.
Each formulation was prepared from 0.67 vol excipient stock
and 0.33 vol protein stock, added to 50 mL Falcon tubes for
ﬁnal concentrations of 0.2 mg/mL GCSF, 1× buﬀer, and 1× of
excipients, and then ﬁltered using 0.2 μm Corning syringe
ﬁlters (Sigma-Aldrich, Gillingham, UK).
Intrinsic Protein Fluorescence and Static Light
Scattering. Intrinsic protein ﬂuorescence (IPF) (266 nm
excitation, 280−450 nm emission scan) and static light
scattering (SLS) at 266 and 473 nm were measured
simultaneously for GCSF using an Optim-1000 (Unchained
Laboratories, Wetherby, UK). measurements were taken at
every 1 °C while ramping the temperature in steps from 15 to
90 °C, at 1 °C per minute. Samples were placed in three 16-
well, 9 μL MCA cuvettes with rubber seals (Avacta Analytical
Plc, Wetherby, UK), allowing 48 samples to be analyzed
simultaneously. Each combination of variant and formulation
was replicated ﬁve times. The barycentric mean ﬂuorescence
intensity, and the SLS counts, each as a function of temperature
were exported into OriginPro 8.6 (Origin Lab Corp.,
Northampton, MA, USA), and replicates averaged prior to
further analysis. Linear ﬁts were applied to the baseline region
of SLS data at the lower temperatures of the curve, and the Tagg
(aggregation onset temperature) taken to be the ﬁrst point that
exceeded two standard deviations above the baseline, along
with all subsequent points. The temperature dependent
barycentric mean ﬂuorescence intensities were ﬁtted to a two-
state transition using eq 1 as previously:9
= + + + − −
+ −( )
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1 4 36 0.1 0 0 0 0 3.5 0 0
2 4 86 0 0.1 0 3 0 3.5 0 50
3 4 36 0.1 0.1 0 3 0 0 50 50
4 4 86 0 0 0 0 0 0 50 0
5 8 36 0 0 0 0 0 0 0 50
6 4 86 0.1 0.1 3 0 0 0 0 50
7 8 86 0.1 0 0 0 0 3.5 50 50
8 4 36 0 0 0 3 3.5 3.5 50 50
9 4 86 0 0 3 0 3.5 3.5 0 50
10 8 86 0.1 0.1 0 3 0 0 0 0
11 8 36 0.1 0 3 3 0 3.5 0 50
12 4 36 0 0 3 3 0 0 0 0
13 8 36 0 0.1 0 3 0 3.5 50 0
14 8 36 0.1 0.1 3 0 0 0 50 0
15 4 36 0 0.1 3 0 0 3.5 50 50
16 8 86 0 0.1 0 0 3.5 0 50 50
17 4 86 0.1 0.1 0 0 3.5 3.5 50 0
18 8 86 0.1 0 3 0 3.5 0 0 0
19 8 36 0 0 3 0 3.5 3.5 50 0
20 8 86 0.1 0.1 3 3 3.5 3.5 50 50
21 4 86 0.1 0 3 3 0 3.5 50 0
22 4 36 0 0.1 0 0 3.5 0 0 0
23 4 36 0.1 0.1 3 3 3.5 3.5 0 0
24 8 36 0.1 0 0 3 3.5 0 50 0
25 8 36 0 0.1 3 3 3.5 0 0 50
26 4 36 0.1 0 3 0 3.5 0 50 50
27 8 36 0.1 0.1 0 0 3.5 3.5 0 50
28 4 86 0 0.1 3 3 3.5 0 50 0
29 8 86 0 0.1 3 0 0 3.5 0 0
30 4 86 0.1 0 0 3 3.5 0 0 50
31 8 86 0 0 3 3 0 0 50 50
32 8 86 0 0 0 3 3.5 3.5 0 0
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where IT is the observed signal, IN and ID are the native and
denatured baseline intercepts, a and b are the native and
denatured baseline slopes, T is the temperature, and Tm is the
apparent midpoint of the observed thermal transition. The data
ﬁt well in all cases to this equation, and so it is assumed that
protein unfolding occurs in a rapid pre-equilibrium, prior to a
relatively slow aggregation step, as observed previously for
GCSF,12 and that this rate of aggregation increases with
temperature to become signiﬁcant on the time scale of the
thermal ramping experiment when signiﬁcant unfolding occurs
close to Tm. Tm reﬂects the equilibrium conformational
unfolding transition, but is convoluted partially by the
aggregation rate, such that it was also dependent on the
thermal ramping rate,12 which was thus kept the same in all
experiments.
The mole-fraction, f T, of unfolded protein at any temperature
T, was calculated from
= − − − + − −f I I bT I aT I bT1 (( )/( ))TT D N D










Ton was deﬁned as the point at which 2% of protein was
calculated to be unfolded, that is, where f Ton = 0.02.
Isothermal Degradation. Wild-type GCSF and the A30G,
A29G/A30G, and A29G/A30G/A37G-GCSF variants were
formulated as above at 0.2 mg/mL, in 18−20 conditions
selected randomly from Table 1, within 2 mL screw-cap HPLC
glass vials (Chromacol Ltd., Welwyn Garden City, UK) with
0.1 mL glass microinserts (VWR International Ltd., Leicester,
UK), and incubated at 37 °C. A total of 30 vials of 100 μL each,
allowed for 10 sacriﬁcial time-points with three replicates of
each formulation. Mass measurements were taken before and
after 37 °C degradation to conﬁrm no evaporation of samples.
Samples removed from the oven were snap-frozen and stored at
−80 °C, and only allowed to be thawed once for analysis by
SEC and the cell activity assay. This process was conﬁrmed to
have no measurable impact on GCSF variant monomer content
or activity. Rates of monomer loss (by SEC) and activity loss
(by activity) were determined as initial velocities (in % day−1)
by linear regression of those data between 0 and up to 20% loss
in each case.
Size Exclusion Chromatography. Size exclusion chroma-
tography (SEC) was carried out by HPLC with a 7.8 × 300
mm2 TSKgel G3000SWXL column (Tosoh Bioscience, Red-
ditch, UK) on an Agilent 1200 workstation (Agilent
Technologies, CA, USA). Samples of 50 μL were centrifuged
at 13 600g for 5 min, then loaded onto the column via the
chilled autosampler. The mobile phase was 0.1 M phosphate
pH 2.5 with a ﬂow rate of 1 mL/min, and GCSF eluted within
25−30 min, as measured by absorbance at 214 and 280 nm.
Monomer peak areas were determined by integration using the
Agilent ChemStation software (Agilent Technologies) and
identiﬁed by comparison to elution of an independently
puriﬁed GCSF reference (NIBSC, Potters Bar, UK).
GNFS-60 Activity Assay. The GNFS-60 cell proliferation
protocol for GCSF potency was carried out as described
previously.27 GNFS-60 cells were grown at 37 °C for 2−3 days,
in T75 ﬂasks (Sigma-Aldrich, Gillingham, UK), containing 20
mL of RPMI-1640 Medium (Sigma-Aldrich, Gillingham, UK),
2 ng/mL r-HuGCSF (Amgen, Uxbridge, UK), 0.5% (v/v)
penicillin−streptomycin (Sigma-Aldrich, Gillingham, UK), and
5% (v/v) fetal bovine serum. Cells were spun down in 50 mL
falcon tubes at 250g for 10 min and resuspended three times to
wash out any residual GCSF, resuspending in 20 mL RPMI-
1640 medium each time, and then counted with a Countess
Automated Cell Counter (Invitrogen, Life Technologies Corp,
Paisley, UK). A 100 μL sample of cells was added to 100 μL of
0.4% Trypan blue (Sigma-Aldrich Co, UK) at room temper-
ature and added immediately to a cell counting chamber slide
with two 10 μL chambers. The cells were diluted to a ﬁnal
concentration of 2 × 105 cells/mL.
Isothermal degradation samples were diluted in RPMI-1640
Medium to a ﬁnal concentration of 4 ng/mL GCSF and 100 μL
loaded into each well across one row of a sterile 96-well plate
(Falcon Microtest (Corning Life Sciences B.V., Amsterdam,
The Netherlands). Samples were then serially diluted into each
row using RPMI-1640 Medium, and 100 μL of the 2 × 105
cells/mL GNFS-60 cells added to all wells, giving 15.6−2000
pg/mL ﬁnal GCSF. Plates were incubated at 37 °C for 48 h,
with a lid to prevent evaporation, and then 20 μL of CellTiter
96AQueous One Solution (Promega, UK) added to each well.
After a further 4−5 h of incubation, the absorbance at 490 nm
was measured in a platereader (Spectramax 340PC, Molecular
Devices LLC, Wokingham, UK) to determine the proliferation
of GNFS-60 cells.
■ RESULTS AND DISCUSSION
Comparison of Thermal Stability Measures Tagg, Tonset,
Tm, and Fraction Unfolded, f . We used nonglycosylated
wild-type (WT) GCSF to ﬁrst evaluate how various short-term
stability measures obtained by thermal ramping were related.
These were compared across a wide range of pH to select the
pH values in which to investigate further formulations. While
GCSF is already known to be most stable at low pH,11,12 we
aimed deliberately to represent a wide range of stabilities and
even potentially diﬀerent aggregation mechanisms.
Thermal transitions were measured simultaneously by static
light-scattering (SLS) at 266 nm, and by intrinsic protein
ﬂuorescence, for WT-GCSF at a range of pH from 3.5−10. SLS
yielded Tagg values, while intrinsic ﬂuorescence was used to
obtain Tm-values, and then also the fraction unfolded, f T, at any
given temperature T. Ton was then deﬁned as the temperature
at which 2% protein was unfolded ( f T = 0.02). We then also
determined the fraction unfolded at Tagg ( f Tagg) for
comparison. Tm-values, measured for aggregation-prone
proteins, are typically a convolution of rapid equilibrium
protein unfolding, and unfolding-induced aggregation kinetics.
They are thus also dependent on the thermal ramping rate, and
so this was kept constant in all experiments.
As shown in Figure 2, WT-GCSF was more stable at lower
pH, as determined by the higher Tm values. This is consistent
with previous literature12 in which GCSF was found not to
adopt a ﬂexible so-called “A-state” at pH 2−4, but rather
exhibited increased folding and higher α-helical content (61%)
at pH 4, compared to 56% at pH 7.12 Ton values were always
lower than Tm, by deﬁnition, and the diﬀerence between them
remained constant at all pH except pH 5, indicating that the co-
operativity of unfolding was generally unaﬀected by pH.
Surprisingly, the Tagg values underwent transitions at pH 3.5
and at pH 6.5 in opposite directions. Tagg values were below Ton
at pH 4−6, and hence, f Tagg was also low (0.5−0.8%),
indicating that heat-induced aggregation of WT-GCSF began
when the protein population was still predominantly native
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(99.2−99.5%). By contrast, Tagg was above Ton at pH 3.5 and
pH 7−10, and even above Tm at pH 10. Accordingly, f Tagg
increased to 6−68%, indicating that heat-induced aggregation
of WT-GCSF began when the population was considerably
unfolded. Therefore, heat-induced aggregation for GCSF was
pH-dependent, as has been observed with other proteins
including A33 Fab,9 and beta2-microglobulin.28
The pI of GCSF is approximately 6,11 and so electrostatic
repulsions between protein molecules would be expected to be
weakest at pH 4−8. This would decrease the solubility of the
protein and increase the rate of aggregation during thermal
ramping, leading to the observed decrease in Tagg. This also
meant that less unfolding could occur, before Tagg was reached,
within the time-scale of the thermal ramping experiment.
Calculations in PropKa (see Table S1, Supporting Information)
actually suggest a lower magnitude for the net charge at pH 8
(−4.6), than at pH 4 (+9.9). However, such calculations ignore
the impact of buﬀer salts on the protein net charge. The
experimental data in Figure 2 suggest that the eﬀective pI could
be closer to 5, to give a true net charge at pH 8 that was slightly
higher than at pH 4, and imparting greater colloidal stability to
aggregation. At lower pH, our results are consistent with
previous observations that GCSF aggregation is strongly
inﬂuenced by an increased colloidal stability.11
The spike in Tm at pH 5 was linked to a Tagg that was the
furthest below Ton than at any other pH, and may indicate an
increased role of a native-like state in heat-induced aggregation
at this pH. Unfolding from the native state was less cooperative
at pH 5 than at all other pH, as indicated by the greater
diﬀerence between Ton and Tm. SLS detected the formation of
heat-induced aggregates (at Tagg), when only 0.5% of GCSF
was unfolded. One explanation is that native GCSF has lower
solubility at pH 5, in part due to being close to the pI of 6, such
that a small population of native protein oligomerizes reversibly
at low temperatures. For example, a reversibly formed dimer
species has been reported under some conditions that does not
participate in irreversible aggregation.13 This dimer formation
would eﬀectively stabilize the native proteins against unfolding
and hence increase the apparent Tm measured by intrinsic
ﬂuorescence, while not aﬀecting Tagg. In general, the heat-
induced aggregation of GCSF appeared to be linked to
unfolding at all pH because Tagg was broadly within the same
temperature range as Ton and Tm, and the lowest f Tagg was
0.005 (0.5%). However, the contribution of aggregation from a
native-like state could not be ruled out, particularly at pH 4−6
where f Tagg was lowest. We therefore aimed to probe this
further by formulating with excipients, and also combining
these with protein mutations that altered the conformational
stability of GCSF.
In addition to this question, Tagg is not necessarily expected
to correlate with aggregation kinetics at lower storage
temperatures, as Tagg is a measure of heat-induced aggregation.
Therefore, we investigated the interrelationships of the various
T-values, fraction unfolded ( f T), and aggregation/inactivation
kinetics, across the range of formulations and mutations. We
decided to limit formulations to only pH 4 and pH 8 as these
had similar Tagg values for WT-GCSF, and yet sampled the
impact of excipients upon aggregation in conditions with low
(Tagg < Ton), and high (Tagg > Ton) populations of unfolded
protein, respectively.
Comparison of Formulation-Averaged <Tagg>,
<Tonset>, <Tm>, and <f Tagg> for GCSF Variants. We
puriﬁed four variants of GCSF, as described previously.24
One single mutant (G26A) had increased conformational
stability, and a series of three variants, A30G, A29G/A30G, and
A29G/A30G/A37G, progressively introduced single destabiliz-
ing mutations. The destabilization of each single mutation is
known to be nonadditive, such that the triple mutant variant is
marginally more conformationally stable than the double
mutant A29G/A30G. The synergistic eﬀects between the
A29G, A30G, and A37G mutations most likely arise from a
local structural reorganization facilitated by increased ﬂexibility
and decreased α-helical propensity in the A-helix.23 This series
of variants therefore presents an opportunity to explore not
only the relationship between conformational stability (ΔG)
and aggregation, but also whether synergistic eﬀects upon
conformational stability translate into synergistic eﬀects in Tagg
or aggregation kinetics.
To discern the relationships between formulation and
protein mutation eﬀects, which are both expected to modify
the conformational stability of GCSF variants, Tagg, Tm, Ton, and
f Tagg values were measured for all four GCSF variants plus WT-
GCSF, within 32 formulations, constructed by design of
experiments (DoE) as described in Table 1. Factors included
pH (50 mM sodium acetate, pH 4, and 50 mM HEPES, pH 8),
ionic strength (36−86 mM), polysorbate concentration (0−
0.1% (v/v) Tween-20 and Tween-80), polyethylene glycol
concentration (0−3 g/L PEG 2000 and PEG 6000),
disaccharide concentration (0−3.5% (w/v) trehalose or
sucrose), and amino-acid concentration (0−50 mM arginine
or glutamic acid).
Tagg, Tm, Ton, and f Tagg values in the 16 formulations at each
pH, were averaged to give <Tagg>, <Tm>, <Ton>, and <f Tagg>
values for each variant at pH 4 and pH 8 separately, for an
overall comparison in Figure 3, to the variant ΔΔGunf (=
ΔGVAR − ΔGWT), obtained previously at pH 4.25. These
average values do not have any speciﬁc thermodynamic
meaning, but allow a simple overall comparison of the behavior
of the GCSF variants. For clarity, the error bars shown are
standard errors of the mean for the values obtained in the 16
formulations and thus represent the precision of this mean
value, whereas the actual spread that contained 95% of all the
values for individual formulations, was four-times larger in all
cases. At both pH 4 and pH 8, <Tm> and <Ton> decreased
linearly as ΔΔGunf increased. Indeed, a comparison of all
Figure 2. (Δ) Tagg, (○) Tm, and (□) Tonset temperatures for wild-type
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ΔΔGunf and Δ<Tm> values (= <Tm>Variant2 − <Tm>Variant1
averaged across all 32 formulations), and between all pairs of
variants (including WT), gave a linear correlation with a
Pearson’s R2-value of 0.98 (Figure S1, Supporting Information).
This conﬁrmed that on average, Tm reports on the conforma-
tional stability of the protein.
At pH 4, <Tagg> was similar to <Ton> for all variants
including WT-GCSF, and <f Tagg> remained low, indicating
heat-induced aggregation from a predominantly, though not
fully, native population. Only three samples had individual
values of f Tagg greater than 20% at pH 4, and these were for the
three least stable variants, in the same formulation comprising
50 mM NaCl, 0.1% (v/v) Tween-80, 0.1% (v/v) Tween-20, 50
mM arginine, 3.5% (v/v) sucrose, and 3.5% (v/v) trehalose.
The variant-averaged fraction unfolded, <f Tagg>, was similar for
the three most stable variants of G26A (3.5%), WT (4%), and
A30G (3%), but then increased to 11% and 7% in A29G/
A30G/A37G and A29G/A30G, respectively, which have similar
ΔΔGunf values of 4.6 kcal mol−1 and 4.8 kcal mol−1,
respectively. This was linked to a small deviation of <Tagg>
above <Ton> by 3 °C for these two variants. Essentially, <Tagg>
remained the same from A30G to A29G/A30G/A37G and
A29G/A30G, while the <Tm> and <Ton> values decreased.
Therefore, the double and triple mutant variants retained a
higher than expected <Tagg>, indicating a retained level of
stability to heat-induced aggregation, despite their lower
conformational stability. The nonadditive behavior of these
mutations upon <Tagg> may be linked to the known
nonadditivity of their ΔΔGunf. However, these eﬀects at pH 4
were relatively small overall.
At pH 8, as observed above for WT, <Tagg> ≈ <Tm>, and
<f Tagg> ranged from 40 to 68%, indicating heat-induced
aggregation from a signiﬁcantly unfolded population in all
variants. The lowest individual value of f Tagg in all formulations
and variants at pH 8 was 2.5%, and the highest was 99%.
Interestingly, <Tagg> was only 2 °C lower at pH 8 than at pH 4
in all variants. However, <Tm> and <Ton> were lower at pH 8
than at pH 4, by 10−12 and 13 °C, respectively. Thus, while
the conformational stability of GCSF variants were signiﬁcantly
lower at pH 8 than at pH 4, the <Tagg> was counterbalanced by
the same colloidal eﬀects described above for WT-GCSF. None
of the variants would be expected to alter the pI of 6, and so the
net charge at pH 8 would remain slightly higher than at pH 4,
imparting greater colloidal stability to aggregation. Hence, a
greater degree of thermal unfolding of the protein was reached
at pH 8, by the time thermal ramping led to heat-induced
aggregation.
The main deviations at pH 8, from linear dependencies on
ΔΔGunf, were in <Tagg> and <Ton>, which consequently created
signiﬁcant increases in <f Tagg> for the three most destabilized
variants. The A30G variant had an unexpectedly lower <Ton>,
indicating a considerable decrease in the cooperativity of
unfolding for this variant at pH 8. This was also observed
directly as shallower slopes in the unfolding transitions for
formulations of this variant, as measured by intrinsic
ﬂuorescence (not shown). This observation points to a
synergistic eﬀect in which the subsequent addition of the
A29G mutation compensated for the A30G mutation, and
restored the unfolding cooperativity. Importantly, these eﬀects
did not impact <Tagg>, which also did not decrease further for
the most destabilizing variants. This strongly indicates colloidal
stabilization eﬀects at pH 8, which limited the impact of
conformational destabilization, when comparing Tagg.
Overall, the generally close link between <Tagg>, <Tm>, and
<Ton> indicated that heat-induced aggregation occurred
predominantly via an unfolded state, at both pH 4 and pH 8,
and in all variants. Furthermore, these results showed that for
the majority of samples, the mutations did not change this
predominant aggregation mechanism at either pH. However,
these data were averaged from 16 formulations each, and so
there may have been individual formulation-variant combina-
tions for which the predominant aggregation mechanism was
altered. Indeed, the lowest value of f Tagg of 0.001%, was found
for G26A at pH 4, in the presence of Tween-80, Tween-20,
PEG 6000, arginine, and glutamate, suggesting an essentially
native protein at Tagg.
Can Thermal Parameters of Formulations for One
Variant Be Used To Predict Those of Another Variant?
We aimed to determine whether the rank order of formulations
determined by any of the individually measured values of Tagg,
Tm, Ton, or f Tagg for one variant would be retained for the other
variants. Such an approach could be useful where newly
engineered molecular variants have promising therapeutic
potential, and where the formulation data for a previous
generation molecule was available. We therefore analyzed the
Pearson’s R2-values for linear correlations, and Spearman’s ρ-
values for rank-order correlations that compared Tagg, Tm, Ton,
f Tagg values for the 32 formulations of each of the ﬁve variants,
against those for each other variant, in all possible pairwise
combinations. Spearman’s correlation coeﬃcients (ρ) were
almost identical to the Pearson’s linear correlation coeﬃcients
(R2) in all cases and so the latter were adopted.
Figure 3. ΔΔGunf of GCSF variants (WT, G26A, A30G, A29G/A30G,
and A29G/A30G/A37G) as measured at pH 4.25,24 compared to their
(●) <Tagg>, (○) <Tm>, (Δ) <Ton> temperatures, and (▲) <f Tagg>,
averaged across the 16 DoE formulations at (A) pH 4 and (B) pH 8.
Error bars denote standard errors of the mean across the 16
formulations, each measured in triplicate. Lines of best ﬁt are shown
for (− −) <Ton> and (- -) <Tm>, and linear interpolations are shown
for (-··-) <f Tagg>.
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To visualize these, we plotted the R2 for each linear
correlation between values from variant 1 and variant 2, against
their respective Δ<Tm> (= <Tm>Variant2 − <Tm>Variant1). All
plots are shown in Figure S2 (Supporting Information). We
found that for all measures (Tagg, Tm, Ton, f Tagg), the R
2-values
decreased as the diﬀerence in <Tm> between the variants
increased and that the smallest decrease was observed with Tm
and f Tagg. For Tm, the R
2-values decreased from 1 at Δ<Tm> = 0
(for all self-correlations) to 0.7, where Δ<Tm> was < −8.8 °C
(Figure 4). For f Tagg, the R
2-values were retained at above 0.87
in 9 of 11 cases, with a value of 0.97 at Δ<Tm> = −8.8 °C, but
also two low values of 0.63 at both Δ<Tm> = −8.0 °C and −5.3
°C. For Tagg, the R
2-values decreased rapidly to below 0.3 where
Δ<Tm> was < −8 °C. None of the R2-values for Tagg exceeded
0.76. For Ton, the R
2-values were mostly in the range 0.65−0.98,
but two values were low at 0.35 where Δ<Tm> = −8 °C, and
0.5 where Δ<Tm> = −5.3 °C, showing poor reliability. Overall,
while f Tagg gave the highest R
2 values on average (0.87), Tm
gave the most consistent trend against Δ<Tm>, while also
retaining high R2 on average (0.8).
Our analysis demonstrated that the Tm values of any ﬁrst
variant of GCSF were a good prediction of those for any
second variant (R2 0.67−0.98) but that this predictive power
decreased as the diﬀerence in their <Tm> increased. Such an
eﬀect indicates that as the diﬀerence in Tm (or ΔΔGunf)
between two variants increases through the accumulation of
mutations, then other eﬀects such as small local structural
reorganizations, also begin to modify the interaction of the
protein with each of the formulation factors, in progressively
less predictable ways. As discussed earlier, this eﬀect appears to
be in part due to the nonadditive impact of the combined
mutations within the double and triple mutant variants, and
demonstrates that even only two or three accumulated
mutations can very rapidly decrease the transferability of
formulation rankings between them.
The rank ordering of formulations by Tm is shown in Figure
5 for all variants, where each line links variants with the same
formulation. Spearman’s correlation coeﬃcients (ρ) that
compare the rank order of formulations between variants and
WT-GCSF were almost identical to the Pearson’s linear
correlation coeﬃcients (R2) in all cases. The red and green
lines denote formulations at pH 4 and 8, respectively. The ρ
(and R2) values for correlations to the WT-GCSF remained
above 0.65 in all cases, and as described above, generally
decreased as the diﬀerence in <Tm> from that of WT-GCSF,
increased.
Independent analysis of the R2 correlations for Tm-values, in
pH 4 and pH 8 formulations, each showed a similar decay with
increasing Δ<Tm> (Figure S1. Supporting Information). The
R2 values at pH 4 (0.26−0.88) were greater than those at pH 8
(0.01−0.82), but the generally lower values than those of the
combined data set indicated that correlations were highly
dependent upon the presence of a signiﬁcant inﬂuence of pH
on the Tm values, relative to the other factors investigated.
Therefore, the rank-ordering of formulations created only at
pH 8 would not be as readily transferrable to a second variant
as those created only at pH 4.
Can Tm, Tagg, Ton, or f Tagg Values for Formulations Be
Used To Predict Degradation Kinetics? Tagg, Tm, or Ton
values are often used as conveniently measured surrogates to
rank-order formulations prior to running longer-term aggrega-
tion kinetics at lower storage temperatures. This approach was
investigated previously for WT-GCSF, in a set of formulations
which generally retained good protein stability,8 and found that
a Tm-value aggregated from multiple biophysical measurements
gave very good predictions of chemical denaturation kinetics
with an R2 of 0.87−0.96 (at 4−40 °C). Our work expands the
range of formulations and variants considerably, and so we re-
evaluated the ability of Tm, but also Tagg, f Tagg, and Ton, to
predict aggregation kinetics.
The aggregation kinetics at 37 °C, for WT-GCSF and the
variants, were monitored by SEC to track monomer loss, and
also by using a cell-proliferation assay to measure the loss of
Figure 4. R2-values obtained by linear correlation of the Tm values
obtained with each formulated variant pair, decrease as their Δ<Tm>
increases. R2-values were obtained by correlating Tm(variant 1) and
Tm(variant 2), for each pair of variants obtained in all formulations.
Δ<Tm> = <Tm>Variant2 − <Tm>Variant1.
Figure 5. Comparison of formulation rank-order between variants.
Top: Tm-values for each formulation. Each line links variants in the
same formulation, and colored for those at pH 4 (red) and pH 8
(green). Bottom: Spearman’s correlation coeﬃcients (ρ) between the
rank order of formulations for variants compared to those obtained for
WT-GCSF, based on Tm values. Standard errors are omitted to retain
clarity, but range from 0.1 to 1.0 °C.
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bioactivity. Wild-type GCSF and the A30G, A29G/A30G, and
A29G/A30G/A37G-GCSF variants were each placed into six
randomly selected DoE formulations (0.2 mg/mL ﬁnal
concentration as used above) and incubated at 37 °C.
Correlation between the initial rates of degradation from the
two measures gave an R2 of 0.65, and a slope of 0.74, indicating
that the rate of activity loss was generally slower than the rate of
monomer loss (Figure 6). It was possible therefore, that some
of the aggregates formed, remained active, or alternatively that
some of the inactive aggregates or vial surface-associated species
could readily dissociate back into active soluble monomers
during the bioassay. The loss of correlation could therefore
have arisen if the various formulations had diﬀerent impacts on
the relative population or reversibility of formation of certain
aggregates.
When plotting only those data for formulations that
contained Tween-80, the R2 value increased to 0.73, and the
slope increased to 0.91. In the absence of Tween-80, the R2
value was only 0.55, and the slope was only 0.5. This indicated
that Tween-80 minimized any formation of reversible
aggregates, or absorption to the vial surface, and hence slowed
the rate of monomer loss to be more consistent with activity
loss.
Linear correlations between Tagg or Tm, Ton, f Tagg and the
initial rates of monomer and activity loss (expressed as ln v) for
each GCSF variant were determined initially using all
formulations tested. Tm gave good correlations to activity and
monomer loss kinetics, with R2 values of 0.73 and 0.77,
respectively. Ton also correlated well, with respective R
2 values
of 0.67 and 0.78 to activity and monomer loss kinetics. By
comparison, all Tagg and f Tagg correlations were poor (R
2 0.17−
0.52). This was mainly due to the eﬀect of Tween-80, which
modiﬁed the Tagg and f Tagg values more signiﬁcantly than the
degradation rates. Figure 7 shows the separate correlations
against degradation rates, for those samples with and without
Tween-80, and this was generally found to improve the R2
values. While samples with and without Tween-80 fell on
distinctly separate lines for Tagg and f Tagg, the impact of Tween-
80 on plots using Tm and Ton was much less statistically
signiﬁcant. In all cases, it can be seen that Tween-80 did not
signiﬁcantly impact the rates of monomer loss or activity loss at
37 °C. Instead, Tween-80 increased Tagg by 8 °C on average,
increased f Tagg accordingly, and had much less impact upon Tm
and Ton. Colloidal stabilization, as measured by Tagg, is expected
with Tween-80, and it is often used to minimize protein−
protein and protein−vial attractions and suppress the formation
of aggregates.29 It was therefore notable that colloidal
stabilization by Tween-80, as measured by Tagg, did not
inﬂuence the degradation rates at 37 °C. The stronger
correlations for f Tagg compared to Tagg for those samples with
and without Tween-80 suggest that f Tagg is the better indicator
for colloidal stabilization, as weakened interactions between
proteins would lead to a greater fraction of unfolded proteins
Figure 6. Comparison of initial rates of loss of activity and monomer,
for GCSF WT and variants in selected formulations at 37 °C. Initial
rates are plotted as natural logs for activity (ln(vact)), and monomer
loss (ln(vmon)). Lines of best ﬁt are shown for all formulations (○ and
●, ), and those in the absence (●,- -) and presence (○,···) of
Tween 80.
Figure 7. Evaluation of the ability of several short-term T-measures to predict the rates of monomer and activity loss for GCSF variants at 37 °C, in a
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required to achieve the same aggregation rate at Tagg. Tween-80
also led to a decrease in some Tm values as expected from a
mild detergent, and yet an unexpected increase in others.
These results were generally consistent with the earlier study
of WT-GCSF formulations at pH 4−5.5,8 in which Tm was
found to correlate well with chemical degradation rates. Here
we have shown that this extended to the comparison of
formulations across single, double, and triple mutant variants
with a range of conformational stabilities, and also for a pH
range up to pH 8. We also found that Tagg and f Tagg
measurements were convoluted by both conformational and
colloidal eﬀects and so less able to predict degradation rates.
Separation of formulations containing excipients expected to
impact on colloidal stability improved the predictions, but this
would not always be possible for more complex formulations.
The contrasting impact of colloidal stabilization upon the
degradation kinetics at 37 °C, and upon Tagg, which generally
occurred at higher than 37 °C, warranted further analysis.
While Tagg measures heat-induced aggregation, and responded
to the impact of Tween-80, Tm was the better predictor of
GCSF formulations in terms of ranking their aggregation
kinetics at 37 °C. This indicates that the aggregation kinetics of
GCSF at 37 °C were strongly linked to global protein
unfolding, as that is directly linked to Tm. The fraction
unfolded at 37 °C ( f T37) was calculated from the same data as
those used to determine Tm, and the inﬂuence of f T37 upon the
initial rates of degradation are shown in Figure 8.
The initial rates of degradation, as measured by either activity
or monomer loss, each generally increased with the fraction of
unfolded protein at the incubation temperature of 37 °C. This
was consistent with the earlier observation that heat-induced
aggregation (at Tagg) also occurred from signiﬁcantly unfolded
protein populations. For a few formulations, the fraction
unfolded at 37 °C fell to below 10−3, and no longer inﬂuenced
the degradation kinetics in this regime. The curvature in the
plot indicates a mechanism switch whereby at f T37 above 10
−3,
aggregation occurred predominantly via global unfolding. Then
in the few conditions with f T37 below 10
−3, including most of
the WT-GCSF formulations, aggregation was more likely to
involve local unfolding of speciﬁc regions of the native state, as
observed previously with other proteins.9,30−32 Previous work
concluded that WT-GCSF aggregation at 37 °C, pH 6.9, does
not occur from the (globally) unfolded state because at 1 M
sucrose (but not at 0 M), the aggregation rate was higher than
the estimated diﬀusion limit for the globally unfolded state.13
On the basis of a transmission coeﬃcient of κ = 1, and a
diﬀusion limited reaction, the reactive species was calculated to
exist as one out of every million molecules in the native state
ensemble.
We ﬁtted our data for the rate of monomer loss in Figure 8
to several kinetic models and found a best ﬁt to one that
combined a diﬀusion-limited bimolecular reaction from a
native-like state in equilibrium with the native state, with a rate-
limiting monomolecular reaction from the unfolded ensemble
into an aggregation-prone conformer (see Figure S3 in
Supporting Information). Consistent with the previous
analysis13 discussed above, we found that under native-like
conditions, the dominant aggregation mechanism was from a
native-like state that was in equilibrium with the native state at
one in every 200 000 native molecules (assuming a trans-
mission coeﬃcient of 1). Of course, not every molecular
collision at the diﬀusion limit would necessarily lead to an
aggregation event, and it is therefore likely that the transmission
coeﬃcient is much less than 1. For example, the transmission
coeﬃcient was estimated previously to be as low as 10−9 for
irreversible aggregation between two clusters of reversibly
formed antibody oligomers.33 This would increase the
population of native-like states accordingly to above one in
every 200 000 and potentially by enough to become directly
observable by the most sensitive biophysical techniques. For
conditions or mutations that promote unfolding, the dominant
aggregation mechanism became one that was rate limited by
conversion of the unfolded population into an aggregation-
prone conformer. The global unfolding rate itself was at least
10-fold faster than the rate of monomer loss at 37 °C and was
therefore not rate limiting (see Supporting Information).
The slowest rate of monomer loss measured at 37 °C for
GCSF was approximately 9% day−1 (ln vmon = 2.2), with f T37 =
1.6 × 10−5, and was obtained for WT in run 8. The fastest at 37
°C was approximately 1300% day−1 (ln vmon = 7.2), with f T37 =
0.18, and was obtained for A29G/A30G in run 19. At 4 °C, for
A29G/A30G in run 19, the fraction unfolded fT4 would be <1 ×
10−8, too low for diﬀusion-limited aggregation, and so for all
variants and formulations studied, the aggregation rates at 4 °C
would no longer be dependent on global protein unfolding. As
the mechanism of aggregation is diﬀerent at 37 and 4 °C, we
would not expect the aggregation rates at 37 °C to give a good
prediction of those under storage at 4 °C, as found in our
previous work with A33 Fab aggregation.9 Formulating for
increased Tm values alone would thus be expected to give little
improvement on the rates of aggregation under low-temper-
ature conditions where the proteins are already more than
99.9% in the native state.
It is noteworthy that the previously reported initial rates of
monomer loss under native conditions for Fab at 4−45 °C were
typically less than 0.13% day−1 (ln vmon < −2), indicating that
aggregation from the native Fab was 66-fold slower than that
from native GCSF under similar conditions. These diﬀerences
most likely resulted from a combination of native protein
properties, such as solubility, surface hydrophobicity, net
charge, local dynamics, and the accessibility of any aggregation
Figure 8. Dependence of initial rates of degradation upon the fraction
unfolded at 37 °C for GCSF variants in a selection of formulations.
Increases in the fraction unfolded at 37 °C ( f T37) lead to increases in
the initial rates of (Δ) activity and (o) monomer loss. The rates of
monomer loss are also colored by variant as (black) WT-GCSF, (dark
gray) A30G, (light gray) A29G/A30G, (white) A29G/A30G/A37G.
Error bars denote the standard deviation of the mean.
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hot-spots, rather than any diﬀerences in their global conforma-
tional stability.
Overall, as a formulation development strategy, it is useful to
increase Tm in the initial stages for poorly stable proteins, at
least up until the mechanistic limit is reached whereby f T37 <
10−3. For degradation of GCSF at 37 °C, this limit was reached
at approximately Tm > 55 °C, where ln vmon < 4 (% day
−1).
Beyond that point, a very diﬀerent formulation strategy would
be required. Protein engineering to remove aggregation
hotspots, minimize local unfolding dynamics, increase the net
charge, or remove hydrophobic surface patches could be
considered.
Inﬂuence of Mutational Synergies on Variant Proper-
ties. Synergistic behaviors appeared in several ways, and we
infer the most likely mechanisms in the absence of further
higher-order structural studies. First, loss of unfolding
cooperativity in A29G at pH 8 indicated at least two
conformations populated in the native state ensemble, as a
result of increased backbone ﬂexibility. Unfolding cooperativity
was restored in A29G/A30G, indicating that a further increase
in backbone ﬂexibility within the same helix, fully depopulated
the original native conformation found in the wild-type.
Second, the <Tm> for A29G/A30G formulations increased by
3.9 °C in the presence of Tween-80, whereas it decreased by
0.8 to 2.1 °C for all other variants. This points to A29G/A30G
having a notably altered native state that can form stabilizing
interactions with Tween-80. Finally, the conformational
stability of A29G/A30G/A37G was slightly greater than for
A29G/A30G, and retained the cooperative unfolding, but
restored the destabilizing eﬀects of Tween-80. The triple
mutant thus appeared to have a native structure conformation
similar to that in WT-GCSF.
■ CONCLUSION
Degradation measured by monomer loss and activity loss for
GCSF at 37 °C, leading to aggregation, occurred via a
population of at least 0.1% unfolded protein in most of the
formulation-variant combinations studied, and the rates were
closely linked to the fraction unfolded at 37 °C ( f T37).
Tm and the associated fraction unfolded f T at the incubation
(storage) temperature were found to be the best parameters by
which to optimize formulations initially, but only up to the
point at which fraction unfolded is less than approximately 0.1−
1%. Tm-values provided a good predictor for activity and
monomer loss kinetics (R2 = 0.73 and 0.77, respectively) for
our GCSF variant-formulation combinations (pH 4−8),
extending previous ﬁndings that Tm could predict the chemical
degradation rates of WT-GCSF formulations at pH 4−5. Tagg
and f Tagg measurements were less able to predict degradation
rates. For example, colloidal stabilization by Tween-80 led to
large increases in Tagg values, but it did not signiﬁcantly
inﬂuence the rates of monomer or activity loss for GCSF at 37
°C. Therefore, Tagg was useful when formulating against
colloidal destabilization, but for GCSF this was only necessary
in conditions where f T was high. However, this might be
expected to become more of an issue for formulations at higher
protein concentrations, at lower ionic strengths, or at pH closer
to the pI, and so Tagg would still be a useful parameter to retain
in formulation screens.
The formulation rank order for one GCSF variant could be
used to predict that of a second variant when based on Tm or
f Tagg values, but not when using Tagg or Ton. Correlations
obtained between variants that diﬀered by up to four A to G
substitutions had R2 values of 0.67−0.98, and the R2 decreased
as the diﬀerence in their <Tm> increased.
The aggregation rates at 37 °C, for all variant-formulation
combinations, were mechanistically dependent on the fraction
unfolded at 37 °C ( f T37) according to a single function.
Individual samples deviated from that function by up to one
order of magnitude in aggregation rates due to diﬀerences in
pH (4 vs 8), mutations, ionic strength, or excipients added.
Such deviations were relatively minor, compared to the range of
aggregation rates explored, but became very signiﬁcant when
ﬁne-tuning formulations to meet clinical requirements. While
the mutations progressively changed the rank order of the
formulations, the rate of aggregation remained uniformly
dependent upon the fraction of unfolded protein, but
transitioned smoothly into a steady baseline rate of aggregation
where formulations of WT-GCSF resulted in a fraction
unfolded at 37 °C of less than 10−3. The baseline rate of
aggregation for GCSF was 66-fold higher than that determined
previously with a Fab antibody fragment. These baseline rates
are likely to be a speciﬁc feature of each native protein,
dependent upon surface properties as well as the dynamics of
local unfolding in speciﬁc regions of the native state, resulting
in a native-like state that for GCSF was present potentially as
low as one in every 200 000 molecules.
While the precise structural mechanisms were not conﬁrmed,
the sequential introduction of A to G mutations that would
alter backbone ﬂexibility resulted in synergistic behaviors and a
fundamental impact on the formulation rank ordering.
However, this nonadditive behavior did not alter the overall
aggregation mechanism or the dependence of the rate of
aggregation on the fraction of unfolded protein.
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